Day

September 28, 2017
More physicians will soon be evaluating an innovative radio frequency (RF) needle developed by Baylis Medical Company Inc. as part of a cross-Canada clinical trial in people with atrial fibrillation (AF). It is the most common heart arrhythmia abnormality and accounts for the majority of arrhythmia-related emergency room visits and hospital admissions. Previous studies have...
Read More

About CANet

CANet is a Pan-Canadian multidisciplinary and multi-sectoral research and development network of investigators, well-positioned industry partners, patients, caregivers, and healthcare providers focused on arrhythmia research, technology development and commercialization, and digital transformation activities.